Possibilities of using Mexidol in the complex therapy of mental disorders

Shamrey, V. K.; Kurasov, E S; Nechiporenko, V.V.; Kolchev, A.I.; Tsygan, N. V.

doi:10.17116/jnevro2020120051160

Cited by 7 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the patient groups did not differ in the psychotropic therapy, we can assume that the decrease in the severity of side effects of the therapy at the end of the study in two groups, receiving the additional medicines, may be due precisely to their action. Previous studies have demonstrated general validity of EMHS for patients with schizophrenia (11,12), whereas the present study represents the first attempt of stratified approach to patients assigned to subgroups with different adjunctive therapy in addition to standard antipsychotic and antidepressant therapy prescribed in LOP. We have succeeded not only in finding clinical features for selecting patients to whom the treatment with EMHS (Gr2) as an adjunctive medicine is favorable, but also in revealing their blood biochemical features discriminating them from other patients with LOP.…”

Section: Discussionmentioning

confidence: 88%

“…One of neuroprotective antioxidant compounds, 2-ethyl-6methyl-3-hydroxypyridine succinate (EMHS), or Mexidol, induces cerebral mitochondriogenesis in aging (7), and inhibits neuronal excitotoxicity in vitro (8). EMHS has been successfully used in complex therapy in neurology (i.e., ischemic brain lesions), infectious pathology (including rehabilitation after COVID-19) (9,10) and psychiatry, including schizophrenia (11,12) and old age psychiatry (13). EMHS is well tolerated, and its ability to prevent or alleviate side effects of antipsychotics, such as tardive dyskinesia, has been reported (11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Late onset psychosis treatment with adjunctive medicines

Boksha,

Savushkina,

Sheshenin

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundA number of studies have shown the feasibility of using adjunctive drugs in late onset psychosis (LOP).AimTesting hypothesis that among LOP people treated with antipsychotics and antidepressants, basing on certain clinical characteristics a subgroup of patients might be distinguished, for whom adjunctive therapy is advantageous. This subgroup might be identified by measurement of blood biochemical parameters.Methods59 in-patients with LOP, treated neuroleptics and antidepressants, were included, and followed in real clinical practice. Database containing demographic, clinical data (scores by PANSS, CDSS, CGI-S, HAMD-17), prescribed therapy, adverse effects of antipsychotic and antidepressant treatment, and blood biochemical parameters (enzymatic activities of glutamate- and glutathione metabolism enzymes in platelets and erythrocytes) at baseline and after the treatment course was created.ResultsThree groups of patients (Gr1, Gr2, and Gr3), based on the adjunctive therapy usage were identified: Gr1 (n = 16) was without adjunctive therapy, two other groups (Gr2 and Gr3) were with adjunctive medicines, such as 2-ethyl-6-methyl-3-hydroxypyridine succinate (EMHS; Gr2, n = 20), or other drugs, such as citicoline, cerebrolysin, cortexin, actovegin, gliatilin (choline alfoscerate; Gr3, n = 23). The enzymatic activities were assessed also in the matched control group (n = 38). In all three patient groups, as compared with controls, activity of erythrocyte glutathione reductase was decreased at baseline and after the treatment course. In Gr2, unlike Gr1 or Gr3, there was a significant decrease in baseline glutamate dehydrogenase and glutathione-S-transferase activities. Certain clinical criteria were also elucidated for prescription of EMHS as adjunctive therapy for patients of Gr2. Glutamate dehydrogenase and glutathione-S-transferase activities returned closer to control levels after the treatment course in Gr2, unlike Gr1, where they declined yet more after psychotropic treatment without adjunctive medicine. Different significant links between biochemical parameters and scores by clinical scales were observed in Gr1, Gr2, and Gr3, some having predictive value for evaluation of antipsychotic treatment efficacy.ConclusionWe demonstrate the validity of adjunctive neuroprotective medicines’ usage in addition to antipsychotic and antidepressant therapy in distinct subgroups of patients suffering with LOP, especially those who have prominent side effects accompanying their psychotropic treatment. Returning of biochemical parameters to control range following the treatment course observed in patients of the subgroup treated with adjunctive EMHS is evidence for their metabolism normalization.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Late onset psychosis treatment with adjunctive medicines

Boksha,

Savushkina,

Sheshenin

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…HAIs that occur while receiving medical care can get into the body through a variety of different portals, such as blood, lungs, skin, urinary tract, or gastrointestinal tract, and lead to serious illness. These infections are difficult to treat, they may persist in the body for a long time, and, in the worst case, become fatal [1,2].…”

Section: ***mentioning

confidence: 99%

“…1, b)in the treatment of mental disorders and neurocognitive deficits, it promotes the inactivation of free radicals and increases the activity of antioxidant enzymes glutathione peroxidase and superoxide dismutase, the level of expression in ischemia of the transcription factor Nrf2, responsible for the resistance of cells to oxidative stress. Succinic acid in the mexidol molecule supports the work of the Krebs cycle succinate oxidase in conditions of oxygen deficiency, binds to its specific receptors (GPR91) and triggers a cascade of biochemical reactions that increase the effectiveness of the drug [1][2][3]. There are a large number of modern antibacterial drugs used in inflammatory and neurodegenerative processes of the human nervous system.…”

Section: Introductionmentioning

confidence: 99%

Spectral characteristics of dexamethasone, mexidol and doxycycline hydrochloride aqueous solutions used separately and in combination

Bayeva,

Radchenko,

Artyukhov

2023

Scientific Achievements of the Third Millennium

View full text Add to dashboard Cite

show abstract

“…На сегодняшний день не существует единого представления о причинах и природе заболевания. В последние годы формируется комплексная модель шизофрении, предполагающая наличие определенной наследственной предрасположенности и биологических, психологических и социальных факторов, влияющих на развитие расстройства [2]. Рассматриваются и исследуются следующие варианты наличия нейробиологических изменений: нарушение обмена нейромедиаторов в головном мозге, процесс нейровоспаления, нейроэндокринные нарушения, процесс нейродегенерации.…”

Section: Introductionunclassified

Pathology of microstructural brain connectivity in paranoid schizophrenia (according to diffusion-tensor tractography data)

Puchkov

Tarumov

Markin

et al. 2021

Russian Military Medical Academy Reports

View full text Add to dashboard Cite

AIM: revealing microstructural brain connectivity alterations in patients with paranoid schizophrenia. MATERIALS AND METHODS: 25 patients diagnosed with paranoid schizophrenia were examined. The control group was 30 healthy people without neurological and somatic diseases. Studies were carried out on the Philips Ingenia magnetic resonance tomograph, with a magnetic field strength of 1.5 T using the DTI pulse sequence. Data processing was carried out using the tractographic module DSI Studio. RESULTS: According to the group assessment of the obtained tractographic brain data, significant differences in microstructural connectivity in the group of patients with paranoid schizophrenia were detected. A pathological conglomerate of cortical-subcortical structure connectivity was found, different from the sets of normal connections in the control group, consisting of a cingulate gyrus, hippocampus and thalamus. Such a pathological control center is one of the possible tractographic patterns of schizophrenia. In our opinion, the pathological connectivity of the hippocampus and thalamus, as one of the main components of the limbic system of the brain, reduces the controlling emotional function of the cingulate cortex, the control center of this system. In this case, excessive connectivity of the hippocampus with the cingulate cortex may indicate an incorrect implementation of their interaction, which also affects the occurrence or progression of emotional-will disorders. The thalamus, being the center of transmission of sensory and motor information from the sensory organs, can transmit incorrect redundant data about what is happening around the body and participate in the formation of auditory and visual hallucinations. Also, the pathological work of the thalamus may be involved in the progression of autism. Thus, the patient is increasingly losing touch with reality, increasingly preferring unknowingly fantasy, erasing ties with reality. Data from one of the characteristics of the artiformal neural network the clustering coefficient were significantly increased in patients compared to the control group, which may indicate the presence of excess, abnormal microstructural connectivity in the network. CONCLUSION: The study confirms the presence of microstructural and neural network changes in the hippocampus, thalamus, cingulate cortex and basal ganglia. These changes are peculiar tractographic semiotic signs of brain pathology in paranoid schizophrenia. This study is a step in the search for a tool to identify the features of neuroplasticity disorders in this disease and schizophrenia screening (2 figures, 3 tables, bibliography: 13 refs).

show abstract

Possibilities of using Mexidol in the complex therapy of mental disorders

Cited by 7 publications

References 7 publications

Late onset psychosis treatment with adjunctive medicines

Late onset psychosis treatment with adjunctive medicines

Spectral characteristics of dexamethasone, mexidol and doxycycline hydrochloride aqueous solutions used separately and in combination

Pathology of microstructural brain connectivity in paranoid schizophrenia (according to diffusion-tensor tractography data)

Contact Info

Product

Resources

About